137. 限局性皮質異形成 Focal cortical dysplasia Clinical trials / Disease details
臨床試験数 : 9 / 薬物数 : 5 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 51
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03198949 (ClinicalTrials.gov) | May 24, 2018 | 13/6/2017 | A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II) | A Prospective, Randomized, Double-blind, Placebo-controlled Cross Over Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II) | Epilepsy and Focal Cortical Dysplasia II | Drug: Afinitor (everolimus) | Yonsei University | NULL | Completed | 4 Years | 40 Years | All | 23 | Phase 2 | Korea, Republic of |